.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,753,706

« Back to Dashboard

Claims for Patent: 5,753,706

Title: Methods for treating renal failure
Abstract:Methods of controlling phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a ferric-containing compound selected from the group consisting of ferric citrate, ferric acetate, and combinations thereof. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.
Inventor(s): Hsu; Chen Hsing (Ann Harbor, MI)
Assignee:
Application Number:08/794,328
Patent Claims: 1. A method of controlling phosphate retention in a patient suffering from hyperphosphatemia or a patient predisposed to development of a hyperphosphatemic condition, comprising the step of administering to the patient a therapeutically-effective amount of a compound selected from the group consisting of ferric citrate, ferric acetate and combinations thereof.

2. The method of claim 1, wherein the compound is administered to the patient orally.

3. The method of claim 1, wherein the compound is ferric citrate.

4. The method of claim 1, wherein the compound is ferric acetate.

5. The method of claim 1, wherein the therapeutically-effective amount of the compound is a unit dosage of about 500 mg to about 1000 mg.

6. A therapeutic composition in oral dosage form for controlling phosphate retention in patients having need for reduced absorption of dietary phosphate, said composition comprising on a per dose basis from about 500 mg to about 1000 mg of a compound selected from the group consisting of ferric citrate, ferric acetate and combinations thereof, and a pharmaceutically acceptable excipient for said oral dosage form.

7. The composition of claim 6, wherein the compound is ferric citrate.

8. The composition of claim 6, wherein the compound is ferric acetate.

9. A method of controlling serum phosphate metabolism and metabolic acidosis in a patient suffering from renal failure, comprising the step of administering to the patient a therapeutically-effective amount of a compound selected from the group consisting of ferric citrate, ferric acetate and combinations thereof.

10. The method of claim 9, wherein the compound is administered to the patient orally.

11. The method of claim 9, wherein the therapeutically-effective amount of the compound is a unit dosage of about 500 mg to about 1000 mg.

12. The method of claim 9, wherein the compound is ferric citrate.

13. The method of claim 9, wherein the compound is ferric acetate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc